is dedicated to enhancing the lives of people with immune thrombocytopenia (ITP) and other platelet disorders through
"Making the world of ITP a more manageable place to be"
PDSA offers support groups across the United States and Canada—and new groups continue to form. Get involved, get support and help others.
PDSA is a community built for you or your loved one with ITP. Find answers on our private discussion group with thousands of members.
Read the latest news about ITP—from breaking updates and survivor stories, to in-depth insights into new treatments and cutting-edge research.
Each September we celebrate ITP Awareness Month℠! Learn how you can join the party to support ITP Awareness Month, Sport Purple for Platelets Day℠ and many other events throughout the United States and world. Participate to elevate ITP awareness and support funding of ITP research and PDSA programs.
"The FDA has accepted Novartis’ supplemental New Drug Application (sNDA) and granted Priority Review designation to Promacta (eltrombopag) in combination with standard immunosuppressive therapy (IST) for first-line treatment of severe aplastic anaemia (SAA), a rare and serious blood condition.
Priority Review designation is used for treatments that address a serious or life-threatening disease or condition…
"One young man is on a mission to gather as many power chords as possible for children who are hospitalized.
It's called Power Jacks, which only makes sense because it was created by 13 year-old Jack Lewy.
Lewy is no stranger to Tulane Lakeside Hosptial for Women and Children in Metairie.
In December, Lewy suffered…
"Novartis Korea said Tuesday additional data analysis from its EXTEND clinical trial for Revolade (ingredient: eltrombopag) proved it safe and effective for those 65 years and older with idiopathic thrombocytopenic purpura (ITP).
The sub-set study findings were presented at the first International Congress of BMT symposium held in Seoul on Aug. 26.
Revolade (known as…
"Protalex, Inc., a clinical-stage biopharmaceutical company, today announced that following a planned interim analysis of data from the second dose cohort of its European Phase 1b study of PRTX-100 in adults with persistent/chronic Immune Thrombocytopenia (ITP) (PRTX-100-203 Study), the Company has initiated enrollment in the third cohort of this dose-escalating study. The first patient in…